The drug discovery firm will work with the Dean Felsher laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
Researchers at Stanford University’s Dean Felsher laboratory have announced plans to collaborate with drug discovery company Pepper Bio in an effort to identify therapeutic targets for untreatable lymphatic and liver cancers. With the help of Pepper Bio’s platform on phosphoproteomics, the collaborators reportedly aim to identify and validate novel targets for hepatocellular carcinoma and lymphoma within the year.
Read on for the full story.
Source: Outsourcing Pharma // See original post here.